The need for new anti-hepatitis C virus therapeutic strategies : targeting the cellular micro-ribonucleic acids?

Abstract EN

Infection with the hepatitis C virus (HCV) is a worldwide problem.

Patients with chronic HCV infection who are non-responders to standard therapy represent a growing population within the HCV epidemic.

Novel, more efficient and tolerable therapies are urgently needed.

This review discusses the recent results showing that targeting miR-122, a micro-ribonucleic acid (MicroRNA) that enhances HCV replication, is a new anti-HCV therapy with a high barrier to resistance.